The repurposed drugs suramin and quinacrine cooperatively inhibit sars-cov-2 3clpro in vitro
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://dx.doi.org/10.3390/v13050873 http://hdl.handle.net/11449/206432 |
Resumo: | Since the first report of a new pneumonia disease in December 2019 (Wuhan, China) the WHO reported more than 148 million confirmed cases and 3.1 million losses globally up to now. The causative agent of COVID-19 (SARS-CoV-2) has spread worldwide, resulting in a pandemic of unprecedented magnitude. To date, several clinically safe and efficient vaccines (e.g., Pfizer-BioNTech, Moderna, Johnson & Johnson, and AstraZeneca COVID-19 vaccines) as well as drugs for emergency use have been approved. However, increasing numbers of SARS-Cov-2 variants make it imminent to identify an alternative way to treat SARS-CoV-2 infections. A well-known strategy to identify molecules with inhibitory potential against SARS-CoV-2 proteins is repurposing clinically developed drugs, e.g., antiparasitic drugs. The results described in this study demonstrated the inhibitory potential of quinacrine and suramin against SARS-CoV-2 main protease (3CLpro ). Quinacrine and suramin molecules presented a competitive and noncompetitive inhibition mode, respectively, with IC50 values in the low micromolar range. Surface plasmon resonance (SPR) experiments demonstrated that quinacrine and suramin alone possessed a moderate or weak affinity with SARS-CoV-2 3CLpro but suramin binding increased quinacrine interaction by around a factor of eight. Using docking and molecular dynamics simulations, we identified a possible binding mode and the amino acids involved in these interactions. Our results suggested that suramin, in combination with quinacrine, showed promising synergistic efficacy to inhibit SARS-CoV-2 3CLpro . We suppose that the identification of effective, synergistic drug combinations could lead to the design of better treatments for the COVID-19 disease and repurposable drug candidates offer fast therapeutic breakthroughs, mainly in a pandemic moment. |
id |
UNSP_d317a8ecdd612ba20cb2cb122b48e4b5 |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/206432 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
The repurposed drugs suramin and quinacrine cooperatively inhibit sars-cov-2 3clpro in vitro3CLproCOVID-19Main proteaseQuinacrineRepurposing approved drugsSARS-CoV-2SuraminSince the first report of a new pneumonia disease in December 2019 (Wuhan, China) the WHO reported more than 148 million confirmed cases and 3.1 million losses globally up to now. The causative agent of COVID-19 (SARS-CoV-2) has spread worldwide, resulting in a pandemic of unprecedented magnitude. To date, several clinically safe and efficient vaccines (e.g., Pfizer-BioNTech, Moderna, Johnson & Johnson, and AstraZeneca COVID-19 vaccines) as well as drugs for emergency use have been approved. However, increasing numbers of SARS-Cov-2 variants make it imminent to identify an alternative way to treat SARS-CoV-2 infections. A well-known strategy to identify molecules with inhibitory potential against SARS-CoV-2 proteins is repurposing clinically developed drugs, e.g., antiparasitic drugs. The results described in this study demonstrated the inhibitory potential of quinacrine and suramin against SARS-CoV-2 main protease (3CLpro ). Quinacrine and suramin molecules presented a competitive and noncompetitive inhibition mode, respectively, with IC50 values in the low micromolar range. Surface plasmon resonance (SPR) experiments demonstrated that quinacrine and suramin alone possessed a moderate or weak affinity with SARS-CoV-2 3CLpro but suramin binding increased quinacrine interaction by around a factor of eight. Using docking and molecular dynamics simulations, we identified a possible binding mode and the amino acids involved in these interactions. Our results suggested that suramin, in combination with quinacrine, showed promising synergistic efficacy to inhibit SARS-CoV-2 3CLpro . We suppose that the identification of effective, synergistic drug combinations could lead to the design of better treatments for the COVID-19 disease and repurposable drug candidates offer fast therapeutic breakthroughs, mainly in a pandemic moment.Universidade Federal de Mato Grosso do SulFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Fundação de Apoio ao Desenvolvimento do Ensino, Ciência e Tecnologia do Estado de Mato Grosso do SulConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Institute of Biological Information Processing (IBI-7 Structural Biochemistry) Forschungszentrum JülichInstitut für Physikalische Biologie Heinrich-Heine-Universität Düsseldorf, UniversitätsstraßeCampus Cimba Federal University of TocantinsInstitute of Physics Federal University of Mato Grosso do SulJuStruct: Jülich Centre for Structural Biology Forchungszentrum JülichMultiuser Center for Biomolecular Innovation IBILCE Universidade Estadual Paulista (UNESP)Multiuser Center for Biomolecular Innovation IBILCE Universidade Estadual Paulista (UNESP)FAPESP: 2016/12904-0FAPESP: 2018/07572-3FAPESP: 2018/12659-0FAPESP: 2019/05614-3Fundação de Apoio ao Desenvolvimento do Ensino, Ciência e Tecnologia do Estado de Mato Grosso do Sul: 23/200.307/2014CNPq: 307338/2014-2CNPq: 401270/2014-9CNPq: 435913/2016-6Forschungszentrum JülichHeinrich-Heine-Universität DüsseldorfFederal University of TocantinsFederal University of Mato Grosso do SulForchungszentrum JülichUniversidade Estadual Paulista (Unesp)Eberle, Raphael J.Olivier, Danilo S.Amaral, Marcos S.Gering, IanWillbold, DieterArni, Raghuvir K. [UNESP]Coronado, Monika A. [UNESP]2021-06-25T10:31:58Z2021-06-25T10:31:58Z2021-01-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://dx.doi.org/10.3390/v13050873Viruses, v. 13, n. 5, 2021.1999-4915http://hdl.handle.net/11449/20643210.3390/v130508732-s2.0-85107200195Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengVirusesinfo:eu-repo/semantics/openAccess2021-10-23T04:34:36Zoai:repositorio.unesp.br:11449/206432Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-05T18:20:35.354916Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
The repurposed drugs suramin and quinacrine cooperatively inhibit sars-cov-2 3clpro in vitro |
title |
The repurposed drugs suramin and quinacrine cooperatively inhibit sars-cov-2 3clpro in vitro |
spellingShingle |
The repurposed drugs suramin and quinacrine cooperatively inhibit sars-cov-2 3clpro in vitro Eberle, Raphael J. 3CLpro COVID-19 Main protease Quinacrine Repurposing approved drugs SARS-CoV-2 Suramin |
title_short |
The repurposed drugs suramin and quinacrine cooperatively inhibit sars-cov-2 3clpro in vitro |
title_full |
The repurposed drugs suramin and quinacrine cooperatively inhibit sars-cov-2 3clpro in vitro |
title_fullStr |
The repurposed drugs suramin and quinacrine cooperatively inhibit sars-cov-2 3clpro in vitro |
title_full_unstemmed |
The repurposed drugs suramin and quinacrine cooperatively inhibit sars-cov-2 3clpro in vitro |
title_sort |
The repurposed drugs suramin and quinacrine cooperatively inhibit sars-cov-2 3clpro in vitro |
author |
Eberle, Raphael J. |
author_facet |
Eberle, Raphael J. Olivier, Danilo S. Amaral, Marcos S. Gering, Ian Willbold, Dieter Arni, Raghuvir K. [UNESP] Coronado, Monika A. [UNESP] |
author_role |
author |
author2 |
Olivier, Danilo S. Amaral, Marcos S. Gering, Ian Willbold, Dieter Arni, Raghuvir K. [UNESP] Coronado, Monika A. [UNESP] |
author2_role |
author author author author author author |
dc.contributor.none.fl_str_mv |
Forschungszentrum Jülich Heinrich-Heine-Universität Düsseldorf Federal University of Tocantins Federal University of Mato Grosso do Sul Forchungszentrum Jülich Universidade Estadual Paulista (Unesp) |
dc.contributor.author.fl_str_mv |
Eberle, Raphael J. Olivier, Danilo S. Amaral, Marcos S. Gering, Ian Willbold, Dieter Arni, Raghuvir K. [UNESP] Coronado, Monika A. [UNESP] |
dc.subject.por.fl_str_mv |
3CLpro COVID-19 Main protease Quinacrine Repurposing approved drugs SARS-CoV-2 Suramin |
topic |
3CLpro COVID-19 Main protease Quinacrine Repurposing approved drugs SARS-CoV-2 Suramin |
description |
Since the first report of a new pneumonia disease in December 2019 (Wuhan, China) the WHO reported more than 148 million confirmed cases and 3.1 million losses globally up to now. The causative agent of COVID-19 (SARS-CoV-2) has spread worldwide, resulting in a pandemic of unprecedented magnitude. To date, several clinically safe and efficient vaccines (e.g., Pfizer-BioNTech, Moderna, Johnson & Johnson, and AstraZeneca COVID-19 vaccines) as well as drugs for emergency use have been approved. However, increasing numbers of SARS-Cov-2 variants make it imminent to identify an alternative way to treat SARS-CoV-2 infections. A well-known strategy to identify molecules with inhibitory potential against SARS-CoV-2 proteins is repurposing clinically developed drugs, e.g., antiparasitic drugs. The results described in this study demonstrated the inhibitory potential of quinacrine and suramin against SARS-CoV-2 main protease (3CLpro ). Quinacrine and suramin molecules presented a competitive and noncompetitive inhibition mode, respectively, with IC50 values in the low micromolar range. Surface plasmon resonance (SPR) experiments demonstrated that quinacrine and suramin alone possessed a moderate or weak affinity with SARS-CoV-2 3CLpro but suramin binding increased quinacrine interaction by around a factor of eight. Using docking and molecular dynamics simulations, we identified a possible binding mode and the amino acids involved in these interactions. Our results suggested that suramin, in combination with quinacrine, showed promising synergistic efficacy to inhibit SARS-CoV-2 3CLpro . We suppose that the identification of effective, synergistic drug combinations could lead to the design of better treatments for the COVID-19 disease and repurposable drug candidates offer fast therapeutic breakthroughs, mainly in a pandemic moment. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-06-25T10:31:58Z 2021-06-25T10:31:58Z 2021-01-01 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.3390/v13050873 Viruses, v. 13, n. 5, 2021. 1999-4915 http://hdl.handle.net/11449/206432 10.3390/v13050873 2-s2.0-85107200195 |
url |
http://dx.doi.org/10.3390/v13050873 http://hdl.handle.net/11449/206432 |
identifier_str_mv |
Viruses, v. 13, n. 5, 2021. 1999-4915 10.3390/v13050873 2-s2.0-85107200195 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Viruses |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.source.none.fl_str_mv |
Scopus reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
|
_version_ |
1808128921921650688 |